Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ENOV
Upturn stock ratingUpturn stock rating

Enovis Corp (ENOV)

Upturn stock ratingUpturn stock rating
$31.36
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: ENOV (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

11 Analysts rated it

Well-followed company, solid analyst reports, reliable data for confident investing.

1 Year Target Price $56.5

1 Year Target Price $56.5

Analysts Price Target For last 52 week
$56.5Target price
Low$28.83
Current$31.36
high$49.83

Analysis of Past Performance

Type Stock
Historic Profit -15.7%
Avg. Invested days 38
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.82B USD
Price to earnings Ratio -
1Y Target Price 56.5
Price to earnings Ratio -
1Y Target Price 56.5
Volume (30-day avg) 11
Beta 1.83
52 Weeks Range 28.83 - 49.83
Updated Date 06/29/2025
52 Weeks Range 28.83 - 49.83
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -14.64

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -37.65%
Operating Margin (TTM) 0.9%

Management Effectiveness

Return on Assets (TTM) 0.92%
Return on Equity (TTM) -27.35%

Valuation

Trailing PE -
Forward PE 10.36
Enterprise Value 3235778560
Price to Sales(TTM) 0.84
Enterprise Value 3235778560
Price to Sales(TTM) 0.84
Enterprise Value to Revenue 1.5
Enterprise Value to EBITDA 22.42
Shares Outstanding 57123100
Shares Floating 56402729
Shares Outstanding 57123100
Shares Floating 56402729
Percent Insiders 1.54
Percent Institutions 117.93

Analyst Ratings

Rating 4
Target Price 56.5
Buy 3
Strong Buy 7
Buy 3
Strong Buy 7
Hold 1
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Enovis Corp

stock logo

Company Overview

overview logo History and Background

Enovis Corp, formerly DJO Global, has a long history in orthopedic and medical technology. Founded in 1982, the company has grown through acquisitions and organic growth to become a leading player in its industry.

business area logo Core Business Areas

  • Reconstructive: Hip, knee and shoulder joint reconstruction devices. Provides products and solutions for large joint reconstruction and bone preserving procedures.
  • Prevention and Recovery: Non-surgical bracing and rehabilitation equipment, including orthopedic bracing, vascular therapy, and pain management solutions. Focuses on products that support injury prevention and post-operative recovery.

leadership logo Leadership and Structure

Matt Trerotola serves as the CEO. The company has a traditional corporate structure with various functional departments, including R&D, sales, marketing, and operations.

Top Products and Market Share

overview logo Key Offerings

  • DJO Bracing and Supports: Orthopedic braces for various body parts, used for injury prevention and rehabilitation. Competitors include Bauerfeind, Ossur, and Breg. Market share data for specific product lines is proprietary.
  • DJO Surgical: Joint reconstruction implants, including hip, knee, and shoulder implants. Competitors include Stryker, Zimmer Biomet, and Johnson & Johnson (DePuy Synthes). Specific market share data is proprietary.
  • DJO Exos: Customizable and waterproof bracing solution. Competitors include conventional casts and splints. Specific market share data is proprietary.

Market Dynamics

industry overview logo Industry Overview

The orthopedic and rehabilitation industry is driven by aging populations, increasing sports-related injuries, and technological advancements in implant materials and surgical techniques. There's a growing demand for minimally invasive procedures and personalized medicine.

Positioning

Enovis Corp holds a strong position in the market, with a focus on innovation and a broad product portfolio. Its competitive advantage lies in its established brand reputation and global distribution network.

Total Addressable Market (TAM)

The global orthopedic device market is expected to reach hundreds of billions of dollars. Enovis is well-positioned to capture a significant portion of this TAM, focusing on segments within reconstructive and preventative/recovery care.

Upturn SWOT Analysis

Strengths

  • Broad product portfolio
  • Strong brand recognition
  • Global distribution network
  • Focus on innovation

Weaknesses

  • Dependence on acquisitions for growth
  • Integration challenges after acquisitions
  • Exposure to regulatory changes
  • Pricing pressure from competitors

Opportunities

  • Expanding into emerging markets
  • Developing new minimally invasive technologies
  • Leveraging data analytics for personalized medicine
  • Partnerships with hospitals and clinics

Threats

  • Increased competition from established players and new entrants
  • Product liability lawsuits
  • Economic downturns affecting healthcare spending
  • Reimbursement pressures from insurance companies

Competitors and Market Share

competitor logo Key Competitors

  • ZBH
  • BSX
  • JNJ

Competitive Landscape

Enovis faces competition from larger, more established players in the orthopedic device market. Its competitive advantage lies in its specialized products and strong customer relationships.

Major Acquisitions

acquired company name

  • Year: 2023
  • Acquisition Price (USD millions): 125
  • Strategic Rationale: Expanded product portfolio and market presence in the regenerative medicine sector.

Growth Trajectory and Initiatives

Historical Growth: Enovis's historical growth has been driven by a combination of organic growth and strategic acquisitions.

Future Projections: Analyst projections suggest continued growth for Enovis, driven by its innovative product portfolio and expansion into new markets.

Recent Initiatives: Recent initiatives include investments in R&D, new product launches, and expansion of its global distribution network.

Summary

Enovis Corp demonstrates a solid market presence with its diversified product offerings. Its growth strategy, incorporating acquisitions, expands its reach. Strong market dynamics and internal strengths support further growth. Vigilance against competition and economic factors are critical for sustained success.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company filings
  • Industry reports
  • Analyst estimates

Disclaimers:

This analysis is based on publicly available information and is not financial advice. Market conditions and company performance are subject to change.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Enovis Corp

Exchange NYSE
Headquaters Wilmington, DE, United States
IPO Launch date 2008-05-08
CEO & Director Mr. Damien McDonald
Sector Healthcare
Industry Medical Devices
Full time employees 7367
Full time employees 7367

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The company's Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. Its Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. It distributes its products through independent distributors and directly under the ESAB and DJO brands. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware.